[Amphastar] February 2026 Monthly Revenue NT$2.238 Billion (YoY +131.5%)
NQ Score
75/100
N1 Content Completeness
8
AI Summary (NQ-processed)
Amphastar (1795) announced astonishing financial results, with February 2026 monthly revenue soaring to NT$2.238 billion, representing a significant year-on-year increase of 131.5%. As a leading generic drug manufacturer in the Asia-Pacific region, this strong performance is likely driven by the success of high-value products such as addiction treatment drugs in overseas markets.
AI analysis data is not yet available.